{"id":"fumaric-acid","rwe":[],"_fda":{"id":"7e90559f-51b5-36ff-e053-2a91aa0a9b17","set_id":"119a205d-0074-48ff-ac78-e2300db45227","openfda":{"nui":["N0000193618","M0001797","N0000185375","N0000185371","N0000175629","N0000184306","M0000728","M0006342","M0016962","M0022575","N0000185017"],"upc":["0317089075202"],"unii":["8ID597Z82X","73Y7P0K73Y","OF5471ZHRR","8L70Q75FXE","PQ6CK8PD0R","CUQ3A77YXI","L7A49804ZQ","N487KM8COK","0UV74P3R0J","SAA04E81UX","K848JZ4886","88XHZ13131","33X04XA5AT","0E53J927NA","817L1N4CKP","VZ3U1H7Q5B","O138UB266J","68Y4CF58BV","TLM2976OFR","6CA025Y4FG","POD38AIF08","AB6MNQ6J6L","398IYQ16YV","9928MC12VO","M572600E5P"],"route":["ORAL"],"spl_id":["7e90559f-51b5-36ff-e053-2a91aa0a9b17"],"brand_name":["OMEOSPORT"],"spl_set_id":["119a205d-0074-48ff-ac78-e2300db45227"],"package_ndc":["17089-075-20"],"product_ndc":["17089-075"],"generic_name":[".ALPHA.-KETOGLUTARIC ACID - ACONITIC ACID, CIS - ADENOSINE TRIPHOSPHATE - ALPHA LIPOIC ACID - ASCORBIC ACID - ASIAN GINSENG - BARIUM CATION - BEET - CEROUS OXALATE NONAHYDRATE - COENZYME A - CYSTEINE - FUMARIC ACID - LACTIC ACID, DL - MAGNESIUM CARBONATE - MALIC ACID - MANGANESE PHOSPHATE, DIBASIC - PORK - PYRIDOXINE HYDROCHLORIDE - RIBOFLAVIN - SODIUM DIETHYL OXALACETATE - SODIUM PYRUVATE - SUCCINIC ACID - SUS SCROFA ADRENAL GLAND - THIAMINE HYDROCHLORIDE - SUS SCROFA EMBRYO -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Ascorbic Acid [CS]","Allergens [CS]","Dietary Proteins [CS]","Plant Proteins [CS]","Vegetable Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]"],"substance_name":[".ALPHA.-KETOGLUTARIC ACID",".ALPHA.-LIPOIC ACID","ACONITIC ACID, (Z)-","ADENOSINE TRIPHOSPHATE","ASCORBIC ACID","ASIAN GINSENG","BARIUM OXALOSUCCINATE","BEET","CEROUS OXALATE NONAHYDRATE","COENZYME A","CYSTEINE","FUMARIC ACID","LACTIC ACID","MAGNESIUM CARBONATE","MALIC ACID","MANGANESE PHOSPHATE, DIBASIC","PORK","PYRIDOXINE HYDROCHLORIDE","RIBOFLAVIN","SODIUM DIETHYL OXALACETATE","SODIUM PYRUVATE","SUCCINIC ACID","SUS SCROFA ADRENAL GLAND","SUS SCROFA EMBRYO","THIAMINE HYDROCHLORIDE"],"pharm_class_epc":["Vitamin C [EPC]","Non-Standardized Plant Allergenic Extract [EPC]","Non-Standardized Food Allergenic Extract [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["USES For the temporary relief of symptoms related to athletic training and exertion such as: Muscle cramps Sore muscles Lack of endurance"],"version":"2","warnings":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days or worsen. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children."],"questions":["QUESTIONS Questions?: info@gunainc.com tel. (484) 223-3500"],"effective_time":"20181221","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE ADENOSINTRIPHOSPHATE 8X CELL METABOLISM ALPHA-KETOGLUTARIC ACID 6X DETOXIFICATION ALPHA-LIPOIC AC 6X DETOXIFICATION ASCORBIC ACID 4X CELL METABOLISM BARIUM OXALOSUCCINATE 6X DETOXIFICATION BETA VULGARIS 2X CELL METABOLISM CERIUM OXALICUM 6X CELL METABOLISM CIS-ACONITIC ACID 6X CELL METABOLISM COENZYME A 6X CELL METABOLISM CYSTEINUM 6X CELL METABOLISM EMBRYO EXTRACT 6X CELL METABOLISM FUMARICUM ACIDUM 6X ANTI-INFLAMMATORY GINSENG 3X DETOXIFICATION GLANDULA SUPRARENALIS 10X HORMONAL REGULATION LACTICUM ACIDUM 8X CELL METABOLISM MAGNESIUM CARBONATE 2X TIREDNESS MALIC ACID 6X CELL METABOLISM MANGANUM PHOSPHORICUM 6X TIREDNESS MUSCLE TISSUE 6X MUSCLE METABOLISM NATRUM OXALACETICUM 6X CELL METABOLISM NATRUM PYRUVICUM 6X CELL METABOLISM PYRIDOXINUM HYDROCHLORICUM 6X METABOLIC SUPPORT RIBOFLAVINUM 6X CELL METABOLISM SUCCINICUM ACIDUM 6X CELL METABOLISM THIAMINUM HYDROCHLORICUM 4X METABOLIC SUPPORT"],"inactive_ingredient":["Inactive ingredient: Sucrose."],"indications_and_usage":["Directions: Turn tube upside down and rotate cap to release pellets into cap. Unscrew cap and without touching pellets tip them into the mouth under the tongue. Allow to dissolve Take 15 minutes before meals."],"dosage_and_administration":["DIRECTIONS Take 15 minutes before meals Adults and children 12 years and older 5 pellets 3 times per day Children between 12 years and 6 years of age 3 pellets 3 times per day Children under 6 years 1 pellet 3 times per day to be dissolved into a little water"],"spl_product_data_elements":["OMEOSPORT .ALPHA.-KETOGLUTARIC ACID - ACONITIC ACID, CIS - ADENOSINE TRIPHOSPHATE - ALPHA LIPOIC ACID - ASCORBIC ACID - ASIAN GINSENG - BARIUM CATION - BEET - CEROUS OXALATE NONAHYDRATE - COENZYME A - CYSTEINE - FUMARIC ACID - LACTIC ACID, DL - MAGNESIUM CARBONATE - MALIC ACID - MANGANESE PHOSPHATE, DIBASIC - PORK - PYRIDOXINE HYDROCHLORIDE - RIBOFLAVIN - SODIUM DIETHYL OXALACETATE - SODIUM PYRUVATE - SUCCINIC ACID - SUS SCROFA ADRENAL GLAND - THIAMINE HYDROCHLORIDE - SUS SCROFA EMBRYO - SUCROSE ADENOSINE TRIPHOSPHATE ADENOSINE TRIPHOSPHATE .ALPHA.-KETOGLUTARIC ACID .ALPHA.-KETOGLUTARIC ACID .ALPHA.-LIPOIC ACID .ALPHA.-LIPOIC ACID ASCORBIC ACID ASCORBIC ACID BARIUM OXALOSUCCINATE BARIUM CATION BEET BEET CEROUS OXALATE NONAHYDRATE CEROUS CATION ACONITIC ACID, (Z)- ACONITIC ACID, (Z)- COENZYME A COENZYME A CYSTEINE CYSTEINE SUS SCROFA EMBRYO SUS SCROFA EMBRYO FUMARIC ACID FUMARIC ACID ASIAN GINSENG ASIAN GINSENG SUS SCROFA ADRENAL GLAND SUS SCROFA ADRENAL GLAND LACTIC ACID LACTIC ACID MAGNESIUM CARBONATE CARBONATE ION MALIC ACID MALIC ACID MANGANESE PHOSPHATE, DIBASIC MANGANESE CATION (2+) PORK PORK SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE SODIUM PYRUVATE PYRUVIC ACID PYRIDOXINE HYDROCHLORIDE PYRIDOXINE RIBOFLAVIN RIBOFLAVIN SUCCINIC ACID SUCCINIC ACID THIAMINE HYDROCHLORIDE THIAMINE ION white"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a health professional before use."],"keep_out_of_reach_of_children":["WARNINGS Keep out of reach of children"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USBIO-Omeosport-rev04-110718"]},"tags":[{"label":"fumaric acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Egl nine homolog 1","category":"target"},{"label":"EGLN1","category":"gene"},{"label":"D05AX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Psoriasis","category":"indication"}],"phase":"marketed","safety":{"boxedWarnings":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FUMARIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:20:18.569175+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:20:23.945761+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FUMARIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:20:24.154185+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:20:17.319962+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:20:17.319987+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:20:17.319993+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL503160/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:20:25.338496+00:00"}},"allNames":"allomaleic acid","offLabel":[],"synonyms":["fumaric acid","2-(E)-butenedioic acid","allomaleic acid"],"timeline":[],"approvals":[],"brandName":"Allomaleic Acid","ecosystem":[{"indication":"Psoriasis","otherDrugs":[{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonia","slug":"ammonia","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""}],"globalPrevalence":125000000}],"mechanism":{"target":"Egl nine homolog 1","targets":[{"gene":"EGLN1","source":"DrugCentral","target":"Egl nine homolog 1","protein":"Egl nine homolog 1"}],"modality":"Small Molecule","drugClass":"Vitamin C [EPC]","explanation":"","oneSentence":"","technicalDetail":"Fumaric Acid exerts its therapeutic effects by inhibiting the activity of Egl nine homolog 1, a key regulator of the hypoxia-inducible factor (HIF) pathway, which is involved in the regulation of cellular responses to hypoxia and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3229","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FUMARIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FUMARIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:37:37.129384","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:20:27.392605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"calcipotriene","drugSlug":"calcipotriene","fdaApproval":"1993-12-29","patentExpiry":"May 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tazarotene","drugSlug":"tazarotene","fdaApproval":"1997-06-13","patentExpiry":"May 11, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ulobetasol propionate","drugSlug":"ulobetasol-propionate","fdaApproval":"1990-12-17","relationship":"same-class"}],"genericName":"fumaric acid","indications":{"approved":[{"name":"Psoriasis","source":"DrugCentral","snomedId":9014002,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"calcipotriene","brandName":"calcipotriene","genericName":"calcipotriene","approvalYear":"1993","relationship":"same-class"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-class"},{"drugId":"tazarotene","brandName":"tazarotene","genericName":"tazarotene","approvalYear":"1997","relationship":"same-class"},{"drugId":"ulobetasol-propionate","brandName":"ulobetasol propionate","genericName":"ulobetasol propionate","approvalYear":"1990","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03331835","phase":"PHASE4","title":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-11-03","conditions":["Psoriasis Vulgaris"],"enrollment":210,"completionDate":"2019-03-21"},{"nctId":"NCT06161688","phase":"PHASE2","title":"Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Timothy Henrich","startDate":"2024-04-09","conditions":["Long COVID","Post Acute Sequelae of COVID-19","Post-Acute COVID-19"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":["Psoriasis","Psoriatic-arthritis"],"enrollment":3500,"completionDate":"2032-12"},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":["Psoriasis"],"enrollment":1121,"completionDate":"2032-03-15"},{"nctId":"NCT05008549","phase":"NA","title":"A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function","status":"COMPLETED","sponsor":"Ocean Spray Cranberries, Inc.","startDate":"2021-07-26","conditions":["Attention","Mood"],"enrollment":25,"completionDate":"2021-11-01"},{"nctId":"NCT02954081","phase":"","title":"APremilast After FumaRic Acid Ester Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-01-26","conditions":["Psoriasis"],"enrollment":687,"completionDate":"2022-08-15"},{"nctId":"NCT05260346","phase":"NA","title":"Modulation of the Gut-brain Axis by Cranberries: Impact on University Students' Mental Wellbeing","status":"COMPLETED","sponsor":"King's College London","startDate":"2022-01-10","conditions":["Healthy"],"enrollment":64,"completionDate":"2022-08-22"},{"nctId":"NCT03107871","phase":"PHASE2","title":"Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert Park","startDate":"2018-08-31","conditions":["Cmv Congenital","CMV","Congenital Cmv","SNHL","Sensorineural Hearing Loss"],"enrollment":52,"completionDate":"2024-07"},{"nctId":"NCT02951533","phase":"PHASE3","title":"A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2016-12-12","conditions":["Psoriasis"],"enrollment":119,"completionDate":"2019-02-06"},{"nctId":"NCT02984397","phase":"PHASE3","title":"Chronic Widespread Pain and White Blood Cell Activation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-12","conditions":["Widespread Chronic Pain"],"enrollment":44,"completionDate":"2020-01"},{"nctId":"NCT02634801","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-01-20","conditions":["Plaque Psoriasis"],"enrollment":162,"completionDate":"2017-11-14"},{"nctId":"NCT02337426","phase":"PHASE1","title":"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-02-13","conditions":["Adult Brain Glioblastoma","Adult Giant Cell Glioblastoma","Adult Gliosarcoma"],"enrollment":12,"completionDate":"2017-11-09"},{"nctId":"NCT02474082","phase":"PHASE3","title":"Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04","conditions":["Psoriasis"],"enrollment":202,"completionDate":"2016-06"},{"nctId":"NCT01812954","phase":"","title":"Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis","status":"COMPLETED","sponsor":"Jochen Schmitt.","startDate":"2013-03","conditions":["Psoriasis"],"enrollment":1,"completionDate":"2014-06"},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":["Psoriasis"],"enrollment":593,"completionDate":"2006-09"},{"nctId":"NCT00466817","phase":"PHASE3","title":"Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-06","conditions":["Cytomegalovirus Infection"],"enrollment":109,"completionDate":"2013-06"},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":["Psoriasis","Inflammatory Bowel Diseases"],"enrollment":222,"completionDate":"2011-01"},{"nctId":"NCT01321164","phase":"PHASE3","title":"Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-04","conditions":["Plaque Psoriasis"],"enrollment":30,"completionDate":"2014-04"},{"nctId":"NCT01352988","phase":"PHASE2","title":"Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2011-07","conditions":["Lupus Erythematosus, Cutaneous"],"enrollment":11,"completionDate":"2014-02"},{"nctId":"NCT01088165","phase":"PHASE4","title":"The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2010-05","conditions":["Psoriasis","Cardiovascular Diseases","Diabetes Mellitus, Type 2"],"enrollment":66,"completionDate":"2014-05"},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":["Pustular Palmoplantar Psoriasis"],"enrollment":20,"completionDate":"2010-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"NUI":"N0000179140","MMSL":"NOCODE","NDDF":"006838","UNII":"88XHZ13131","VUID":"4020189","CHEBI":"CHEBI:18012","VANDF":"4020189","RXNORM":"25389","UMLSCUI":"C0060825","chemblId":"CHEMBL503160","ChEMBL_ID":"CHEMBL503160","KEGG_DRUG":"D02308","DRUGBANK_ID":"DB01677","PDB_CHEM_ID":" FUM","PUBCHEM_CID":"444972","MESH_SUPPLEMENTAL_RECORD_UI":"C032005"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1958,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"D05AX01","allCodes":["D05AX01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:20:27.392605+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}